Direct comparison
Pediatrics vs Geriatrics: Research Differences
Pediatrics studies children; geriatrics studies older adults. Compare consent, assent, Subpart D, NIH inclusion policy, funders, endpoints and trial design.
Written and maintained by CASRAI Editorial Board
Last updated
Ask CASRAI · free to try
Ask about Pediatrics vs Geriatrics: Research Differences
Ask your first 2 questions free below. Subscribers get 150 a day for $29 a month.
An AI assistant specialized in research administration. It cites the sources behind every answer, labels web answers and says when it can't answer.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays free to read, with no account and no card.
How do Pediatrics, Geriatrics compare side by side?
The table below compares Pediatrics, Geriatrics across 13 procurement-relevant dimensions, from population through overlap and when to use which.
Side-by-side comparison
| Dimension | Pediatrics | Geriatrics |
|---|---|---|
| Population | Infants, children and adolescents, from birth through the end of adolescence. Normal differs by age: what is normal for a newborn is abnormal for a toddler or a teenager, so developmental stage is a design variable in nearly every study. | Older adults, especially those living with several chronic conditions, changes in thinking or mobility, and complicated medication regimens. Chronological age is a weak guide; people of the same age vary widely in frailty and function. |
| Research-ethics framework | Children are a core vulnerable population. In the US, federally supported research follows the Common Rule (45 CFR Part 46), whose Subpart D adds child-specific protections; FDA-regulated studies follow 21 CFR Part 50. The ethical base is the Belmont Report. | No age-specific subpart. Older adults are covered by the general Common Rule and FDA protections. Extra attention applies where decision-making capacity may be impaired, and IRBs review such studies for safeguards proportionate to that risk. |
| Consent model | Two separate things replace adult consent: parental permission (a parent or guardian agrees) and assent (the child affirmatively agrees). Under 45 CFR 46.408 the IRB decides whether children can assent, considering age, maturity and psychological state, and assent may be waived in defined circumstances. Re-consent is typically planned for when a child reaches the age of majority. | The adult consents personally, on the presumption of capacity. Where capacity is in doubt, protocols describe how it will be assessed, and where it is lacking a legally authorized representative may agree on the person's behalf, with the participant's own assent sought where possible. Who qualifies as a representative depends on applicable state and local law. |
| Risk-category rules | Subpart D allows IRB approval only within four categories: 46.404 (no greater than minimal risk), 46.405 (greater than minimal risk with prospect of direct benefit), 46.406 (a minor increase over minimal risk, no direct benefit, likely to yield generalizable knowledge about the child's condition) and 46.407 (not otherwise approvable, referred for federal-level review). One parent's permission suffices for 46.404 and 46.405; both are required for 46.406 and 46.407, with stated exceptions. | No equivalent category scheme. The general approval criteria apply (risks minimized and reasonable relative to benefits, equitable selection, informed consent, monitoring). Data and safety monitoring is often emphasized because older populations have a higher baseline risk of adverse events. |
| Inclusion policy | NIH has long expected inclusion of children. The Inclusion Across the Lifespan policy (NOT-OD-18-116, effective January 2019) extended that to all ages. Excluding children needs a scientific or ethical justification, and the application must say so. | Section 2038 of the 21st Century Cures Act (December 13, 2016) directed NIH to address age as an inclusion variable, leading to the same policy. Older adults were historically under-enrolled because of upper age limits and exclusions for comorbidity, disability or concurrent medication; age-based exclusions now need justification rather than default use. |
| Regulatory incentives for drug studies | Dedicated US laws: the Best Pharmaceuticals for Children Act (BPCA) is a voluntary incentive for studying drugs in children, and the Pediatric Research Equity Act (PREA) requires pediatric assessment for certain applications unless FDA grants a waiver or deferral. The EU parallel is the paediatric investigation plan. ICH E11A (August 2024) harmonizes pediatric extrapolation. Details change with legislation; check current FDA guidance. | No age-specific incentive or mandate comparable to BPCA/PREA. The main lever is inclusion policy and trial design: representative enrollment, fewer blanket exclusions, and attention to older participants in pivotal trials so labeling reflects the people who will use the drug. |
| Typical endpoints and outcomes | Age-dependent: growth, developmental milestones, school and behavioral outcomes, age-appropriate pain and symptom scales, and often parent- or clinician-reported measures for young children who cannot self-report. Long-term follow-up for late effects is common. | Patient-centered and functional: independence, mobility, falls, cognition, quality of life and hospitalization, often weighed above a single-disease laboratory value. Competing risks (death before the event of interest) and attrition must be handled in the analysis. |
| Assessment tools (general terms) | Developmental screening and milestone checklists, growth charts, validated age-banded questionnaires, and bedside tools such as the Apgar score at birth. Instruments must be validated for the specific age band used. | Brief cognitive screens (Mini-Cog, Montreal Cognitive Assessment), function and mobility measures (Timed Up and Go, Katz Index of Activities of Daily Living), frailty instruments (for example the Clinical Frailty Scale) and comprehensive geriatric assessment. Frailty has no single universal definition, so protocols must state the one used. |
| Trial-design challenges | Smaller eligible populations (especially rare diseases), age-appropriate formulations and dosing that cannot simply be scaled down from adults, ethics review stricter than for adults, and recruitment that depends on parents. Common answers are multi-site networks, pooled designs and extrapolation from adult data. | Multimorbidity and polypharmacy complicate eligibility, attribution of adverse events and interaction risk; narrow trials miss typical patients. Participation barriers include transport, sensory impairment, caregiver involvement and visit burden. Longitudinal designs over years raise attrition and mortality problems. |
| Multimorbidity and polypharmacy | Less central, though children with chronic or congenital conditions and medical complexity do exist. The larger medication issue is developmental pharmacology: absorption, metabolism and clearance change with age, and many drugs have been used off label in children. | Central. Several coexisting conditions and many concurrent medications are the norm. Polypharmacy is judged by appropriateness, not drug count; explicit criteria such as the AGS Beers Criteria and the STOPP/START criteria support review and deprescribing research. |
| Primary US funders | The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, founded 1962) is the largest dedicated public funder and administers NIH activity under BPCA. Many disease-focused NIH institutes also fund pediatric work, as do foundations, hospitals and industry. | The National Institute on Aging (NIA, established 1974) is the lead federal funder of aging research, including clinical geriatrics. Other NIH institutes (cancer, cardiovascular, mental health) fund work involving older adults, alongside foundations and professional societies. |
| Societies, training and careers | American Academy of Pediatrics (founded 1930), the American Board of Pediatrics, and subspecialty societies. Path: medical school, pediatric residency, board certification, optional subspecialty fellowship. Non-physician routes include pediatric nursing, child psychology, developmental science and biostatistics. | American Geriatrics Society (founded 1942), Gerontological Society of America and, in the UK, the British Geriatrics Society. Path: medical school, internal medicine or family medicine residency, then a one-year geriatric medicine fellowship. Other routes include geriatric nursing, pharmacy, therapy and social work. |
| Overlap and when to use which | Both are age-defined fields that share family medicine and public health as neighbors, and both need lifespan-wide thinking about consent, vulnerability and inclusion. Use "pediatrics" when the participants are children or adolescents, Subpart D applies, or the topic is BPCA/PREA and pediatric drug development. | Geriatrics is the clinical counterpart of gerontology, the broader science of aging (see the geriatrics vs gerontology comparison). Use "geriatrics" when participants are older adults, capacity and surrogate consent are in play, or the topic is multimorbidity, polypharmacy, frailty and NIH inclusion of older people. |
Common questions
Common questions about Pediatrics vs Geriatrics
What is the main difference between pediatrics and geriatrics?
+
Pediatrics is the medical specialty and research field for infants, children and adolescents; geriatrics is the specialty and research field for older adults. Beyond age, they differ in how research participants are protected (parental permission and assent versus capacity and surrogate consent), in the scientific problems they face (development versus multimorbidity and frailty) and in their lead US funders (NICHD versus NIA).
What is the difference between consent, assent and parental permission?
+
Informed consent is a competent adult's own agreement to take part. In research with children, 45 CFR 46 Subpart D separates parental permission, which is a parent or guardian's agreement, from assent, which is the child's own affirmative agreement. The IRB decides whether assent is required based on the children's ages, maturity and psychological state, and it can be waived in defined circumstances.
Does Subpart D apply to older adults?
+
No. Subpart D concerns children. Older adults are covered by the general protections of the Common Rule and FDA regulations. Where an older adult may lack decision-making capacity, the protocol and IRB review address how capacity will be assessed and whether a legally authorized representative may consent, according to applicable state and local law.
What does the NIH Inclusion Across the Lifespan policy require?
+
Under notice NOT-OD-18-116, effective January 2019, NIH-funded studies are expected to include participants of all ages, children and older adults among them, unless there are scientific or ethical reasons for exclusion. Age-based exclusions need to be justified rather than applied by default. It followed Section 2038 of the 21st Century Cures Act. Check the current NIH notice and funding opportunity for exact wording.
Why are there special laws for pediatric drug studies but not for older adults?
+
Children were long treated with drugs never studied in them, so Congress created the Best Pharmaceuticals for Children Act (an incentive) and the Pediatric Research Equity Act (a requirement for certain applications). Older adults are addressed mainly through inclusion policy and trial design rather than a dedicated incentive. Specific provisions change with legislation, so consult FDA's current guidance.
Why do multimorbidity and polypharmacy matter more in geriatric research?
+
Older adults often live with several conditions and take many medications at once. That complicates eligibility (a narrow trial excludes typical patients), makes adverse events harder to attribute and raises interaction risk. Researchers therefore need to define how multimorbidity and polypharmacy are measured and, for medicines, assess appropriateness using explicit criteria such as the AGS Beers Criteria.
Which NIH institute funds which?
+
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the largest dedicated US public funder of pediatric research, and the National Institute on Aging (NIA) leads federal funding for aging research. Both are part of NIH, and other institutes organized by disease or organ system also fund studies of children and older adults.
